Suppr超能文献

内在和外在因素对抗体药物偶联物(ADCs)药代动力学的影响。

Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibody-Drug Conjugates (ADCs).

作者信息

Mahmood Iftekhar

机构信息

Mahmood Clinical Pharmacology Consultancy, LLC., Rockville, MD 20850, USA.

出版信息

Antibodies (Basel). 2021 Oct 15;10(4):40. doi: 10.3390/antib10040040.

Abstract

Antibody-drug conjugates (ADCs) are complex molecules wherein a monoclonal antibody is linked to a biologically active drug (a small molecule), forming a conjugate. Initially, most of the ADCs were developed and are being developed for the treatment of cancer; however, with time, it has been realized that ADCs can also be developed to manage or cure other diseases. Pharmacokinetics (PK) plays an important role in modern-day drug development and the knowledge of PK is crucial in designing a safe and efficacious dose to treat a wide variety of diseases. There are several factors that can alter the PK of a drug; as a result, one has to adjust the dose in a patient population. These factors can be termed 'intrinsic' or 'extrinsic'. For small molecules, the impact of both intrinsic and extrinsic factors is well established. The impact of age, gender, disease states such as renal and hepatic impairment, drug-drug interaction, food, and in many cases alcohol on the PK of small molecules are well known. On the other hand, for macromolecules, the impact of these factors is not well established. Since the ADCs are a combination product of a monoclonal antibody linked to a small molecule, both the small molecule and the monoclonal antibody of the ADCs may be subjected to many intrinsic and extrinsic factors. This review summarizes the impact of intrinsic and extrinsic factors on the PK of ADCs and the payloads.

摘要

抗体药物偶联物(ADCs)是复杂的分子,其中单克隆抗体与生物活性药物(小分子)相连,形成偶联物。最初,大多数ADC是为癌症治疗而开发的,并且仍在开发中;然而,随着时间的推移,人们意识到ADC也可用于治疗或治愈其他疾病。药代动力学(PK)在现代药物开发中起着重要作用,PK知识对于设计安全有效的剂量以治疗各种疾病至关重要。有几个因素可以改变药物的PK;因此,必须在患者群体中调整剂量。这些因素可分为“内在”或“外在”因素。对于小分子,内在和外在因素的影响已得到充分证实。年龄、性别、疾病状态(如肾和肝功能损害)、药物相互作用、食物以及在许多情况下酒精对小分子PK的影响是众所周知的。另一方面,对于大分子,这些因素的影响尚未得到充分证实。由于ADC是与小分子相连的单克隆抗体的组合产品,ADC的小分子和单克隆抗体都可能受到许多内在和外在因素的影响。本综述总结了内在和外在因素对ADC及其有效载荷PK的影响。

相似文献

1
Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibody-Drug Conjugates (ADCs).
Antibodies (Basel). 2021 Oct 15;10(4):40. doi: 10.3390/antib10040040.
3
Clinical Pharmacology of Antibody-Drug Conjugates.
Antibodies (Basel). 2021 May 21;10(2):20. doi: 10.3390/antib10020020.
4
Introduction to Antibody-Drug Conjugates.
Antibodies (Basel). 2021 Oct 27;10(4):42. doi: 10.3390/antib10040042.
5
Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):537-548. doi: 10.1007/s10928-017-9544-y. Epub 2017 Sep 16.
6
7
Challenges and advances in the assessment of the disposition of antibody-drug conjugates.
Biopharm Drug Dispos. 2016 Mar;37(2):66-74. doi: 10.1002/bdd.1957. Epub 2015 Jun 8.
9
Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.
Pharm Res. 2015 Nov;32(11):3541-71. doi: 10.1007/s11095-015-1704-4. Epub 2015 May 19.

本文引用的文献

1
Clinical Pharmacology of Antibody-Drug Conjugates.
Antibodies (Basel). 2021 May 21;10(2):20. doi: 10.3390/antib10020020.
2
Does Hepatic Impairment Affect the Exposure of Monoclonal Antibodies?
Clin Pharmacol Ther. 2020 May;107(5):1256-1262. doi: 10.1002/cpt.1765. Epub 2020 Jan 28.
3
Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety.
Clin Pharmacol Drug Dev. 2019 Apr;8(3):281-289. doi: 10.1002/cpdd.650. Epub 2019 Jan 24.
4
Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
Adv Ther. 2017 May;34(5):1015-1035. doi: 10.1007/s12325-017-0519-6. Epub 2017 Mar 30.
5
Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma.
Cancer Chemother Pharmacol. 2016 Dec;78(6):1217-1223. doi: 10.1007/s00280-016-3180-x. Epub 2016 Nov 11.
6
Pharmacokinetic Considerations in Designing Pediatric Studies of Proteins, Antibodies, and Plasma-Derived Products.
Am J Ther. 2016 Jul-Aug;23(4):e1043-56. doi: 10.1097/01.mjt.0000489921.28180.b9.
8
Antibody-drug conjugates for non-oncological indications.
Expert Opin Biol Ther. 2016;16(5):591-3. doi: 10.1517/14712598.2016.1161753. Epub 2016 Mar 21.
9
Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies.
MAbs. 2014 Jul-Aug;6(4):859-70. doi: 10.4161/mabs.28965. Epub 2014 Apr 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验